nach oben

Clinical & Translational Metabolism

Erschienen in:

05.02.2018 | Review Paper

Glucocorticoid Excess in Bone and Muscle

verfasst von: Amy Y. Sato, Munro Peacock, Teresita Bellido

Erschienen in: Clinical & Translational Metabolism | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Glucocorticoids (GC), produced and released by the adrenal glands, regulate numerous physiological processes in a wide range of tissues. Because of their profound immunosuppressive and anti-inflammatory actions, GC are extensively used for the treatment of immune and inflammatory conditions, the management of organ transplantation, and as a component of chemotherapy regimens for cancers. However, both pathologic endogenous elevation and long-term use of exogenous GC are associated with severe adverse effects. In particular, excess GC has devastating effects on the musculoskeletal system. GC increase bone resorption and decrease formation leading to bone loss, microarchitectural deterioration, and fracture. GC also induce loss of muscle mass and strength leading to an increased incidence of falls. The combined effects on bone and muscle account for the increased fracture risk with GC. This review summarizes the advance in knowledge in the last two decades about the mechanisms of action of GC in bone and muscle and the attempts to interfere with the damaging actions of GC in these tissues with the goal of developing more effective therapeutic strategies.

Plotz CM, Knowlton AI, Ragan C. The natural history of Cushing's syndrome. Am J Med. 1952;13(5):597–614. https://doi.org/10.1016/0002-9343(52)90027-2.PubMedCrossRef

Soffer LJ, Iannacconone A, Gabrilove JL. Cushing's syndrome. Am J Med. 1961;30:129–46.CrossRef

Ross EJ, Linch DC. Cushing's syndrome--killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet. 1982;2:646–9.PubMedCrossRef

Littooij AS, Kwee TC, Enriquez G, et al. Whole-body MRI reveals high incidence of osteonecrosis in children treated for Hodgkin lymphoma. Br J Haematol. 2017;176(4):637–42. https://doi.org/10.1111/bjh.14452.PubMedCrossRef

Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of long-course oral corticosteroids in children. PLoS One. 2017;12(1):e0170259. https://doi.org/10.1371/journal.pone.0170259.PubMedPubMedCentralCrossRef

Gudbjornsson B, Juliusson UI, Gudjonsson FV. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis. 2002;61(1):32–6. https://doi.org/10.1136/ard.61.1.32.PubMedPubMedCentralCrossRef

Overman RA, Gourlay ML, Deal CL, et al. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis. Osteoporos Int. 2015;26:1515–24.PubMedPubMedCentralCrossRef

Canalis E, Mazziotti G, Giustina A, et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18:1319–28.PubMedCrossRef

Batchelor TT, Taylor LP, Thaler HT, et al. Steroid myopathy in cancer patients. Neurology. 1997;48:1234–8.PubMedCrossRef

10.

Bowyer SL, LaMothe MP, Hollister JR. Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol. 1985;76:234–42.PubMedCrossRef

11.

Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003;48(11):3224–9. https://doi.org/10.1002/art.11283.PubMedCrossRef

12.

Weinstein RS, Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011;365:(1)62–70. https://doi.org/10.1056/NEJMcp1012926.

13.

Chapman K, Holmes M, Seckl J. 11beta-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. Physiol Rev. 2013;93:1139–206.PubMedPubMedCentralCrossRef

14.

Charmandari E, Kino T, Chrousos GP. Primary generalized familial and sporadic glucocorticoid resistance (Chrousos syndrome) and hypersensitivity. Endocr Dev. 2013;24:67–85. https://doi.org/10.1159/000342505.PubMedPubMedCentralCrossRef

15.

Tomlinson JW, Draper N, Mackie J, et al. Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion. J Clin Endocrinol Metab. 2002;87:57–62.PubMed

16.

Arai H, Kobayashi N, Nakatsuru Y, et al. A case of cortisol producing adrenal adenoma without phenotype of Cushing's syndrome due to impaired 11beta-hydroxysteroid dehydrogenase 1 activity. Endocr J. 2008;55:709–15.PubMedCrossRef

17.

Draper N, Walker EA, Bujalska IJ, et al. Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet. 2003;34:434–9.PubMedCrossRef

18.

Lavery GG, Idkowiak J, Sherlock M, et al. Novel H6PDH mutations in two girls with premature adrenarche: 'apparent' and 'true' CRD can be differentiated by urinary steroid profiling. Eur J Endocrinol. 2013;168:K19–26.PubMedPubMedCentralCrossRef

19.

Morgan SA, Hassan-Smith ZK, Lavery GG. Mechanisms in endocrinology: tissue-specific activation of cortisol in Cushing's syndrome. Eur J Endocrinol. 2016;175:R83–9.PubMedCrossRef

20.

Swartz SL, Dluhy RG. Corticosteroids: clinical pharmacology and therapeutic use. Drugs. 1978;16(3):238–55. https://doi.org/10.2165/00003495-197816030-00006.PubMedCrossRef

21.

Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med. 1999;159(9):941–55. https://doi.org/10.1001/archinte.159.9.941.PubMedCrossRef

22.

Crilly RG, Marshall DH, Nordin BE. Metabolic effects of corticosteroid therapy in post-menopausal women. J Steroid Biochem. 1979;11:429–33.PubMedCrossRef

23.

Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid- induced bone loss. J Bone Miner Res. 1992;7:1063–9.PubMedCrossRef

24.

Crilly RG, Marshall DH, Horsman A, Nordin BEC, Peacock M. Corticosteroid Osteoporosis. In: Dixon ASJ, Russell RGG, Stamp TCB, editors. Osteoporosis, A Multi-Disciplinary Problem. London: Academic press Inc and Royal Society of Medicine; 1983. p. 153–9.

25.

Oikarinen A, Haapasaari KM, Sutinen M, et al. The molecular basis of glucocorticoid-induced skin atrophy: topical glucocorticoid apparently decreases both collagen synthesis and the corresponding collagen mRNA level in human skin in vivo. Br J Dermatol. 1998;139:1106–10.PubMedCrossRef

26.

Schwartz AV. Diabetes mellitus: does it affect bone? Calcif Tissue Int. 2003;73(6):515–9. https://doi.org/10.1007/s00223-003-0023-7.PubMedCrossRef

27.

Cooper MS. Glucocorticoids in bone and joint disease: the good, the bad and the uncertain. Clin Med (Lond). 2012;12(3):261–5. https://doi.org/10.7861/clinmedicine.12-3-261.CrossRef

28.

Shi L, Sanchez-Guijo A, Hartmann MF, et al. Higher glucocorticoid secretion in the physiological range is associated with lower bone strength at the proximal radius in healthy children: importance of protein intake adjustment. J Bone Miner Res. 2015;30:240–8.PubMedCrossRef

29.

Cooper MS, Rabbitt EH, Goddard PE, et al. Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res. 2002;17:979–86.PubMedCrossRef

30.

Cooper MS, Syddall HE, Fall CH, et al. Circulating cortisone levels are associated with biochemical markers of bone formation and lumbar spine BMD: the Hertfordshire cohort study. Clin Endocrinol. 2005;62:692–7.CrossRef

31.

van Schoor NM, Dennison E, Lips P, Uitterlinden AG, Cooper C. Serum fasting cortisol in relation to bone, and the role of genetic variations in the glucocorticoid receptor. Clin Endocrinol. 2007;67(6):871–8. https://doi.org/10.1111/j.1365-2265.2007.02978.x.CrossRef

32.

Suman OE, Spies RJ, Celis MM, et al. Effects of a 12-wk resistance exercise program on skeletal muscle strength in children with burn injuries. J Appl Physiol (1985). 2001;91:1168–75.CrossRef

33.

Przkora R, Herndon DN, Sherrard DJ, et al. Pamidronate preserves bone mass for at least 2 years following acute administration for pediatric burn injury. Bone. 2007;41:297–302.PubMedPubMedCentralCrossRef

34.

Norbury WB, Herndon DN, Branski LK, et al. Urinary cortisol and catecholamine excretion after burn injury in children. J Clin Endocrinol Metab. 2008;93:1270–5.PubMedPubMedCentralCrossRef

35.

Besemer F, Pereira AM, Smit JW. Alcohol-induced Cushing syndrome. Hypercortisolism caused by alcohol abuse. Neth J Med. 2011;69:318–23.PubMed

36.

Van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res. 2001;16(3):581–8. https://doi.org/10.1359/jbmr.2001.16.3.581.PubMedCrossRef

37.

Van Staa TP, Abenhaim L, Cooper C, et al. Public health impact of adverse bone effects of oral corticosteroids. Br J Clin Pharmacol. 2001;51(6):601–7. https://doi.org/10.1046/j.0306-5251.2001.bjcp.1385.x.PubMedPubMedCentralCrossRef

38.

Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral corticoisteroids and risk of fractures. J Bone Miner Res. 2000;15(6):993–1000. https://doi.org/10.1359/jbmr.2000.15.6.993.PubMedCrossRef

39.

Walsh LJ, Wong CA, Oborne J, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax. 2001;56:279–84.PubMedPubMedCentralCrossRef

40.

Hubbard RB, Smith CJ, Smeeth L, et al. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med. 2002;166:1563–6.PubMedCrossRef

41.

Van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2006;79(3):129–37. https://doi.org/10.1007/s00223-006-0019-1.PubMedCrossRef

42.

Luengo M, Picado C, Del Rio L, et al. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax. 1991;46:803–6.PubMedPubMedCentralCrossRef

43.

Selby PL, Halsey JP, Adams KR, et al. Corticosteroids do not alter the threshold for vertebral fracture. J Bone Miner Res. 2000;15:952–6.PubMedCrossRef

44.

Yang S, Shen X. Association and relative importance of multiple obesity measures with bone mineral density: the National Health and nutrition examination survey 2005-2006. Arch Osteoporos. 2015;10(1):14. https://doi.org/10.1007/s11657-015-0219-2.PubMedCrossRef

45.

Zhu K, Hunter M, James A, et al. Associations between body mass index, lean and fat body mass and bone mineral density in middle-aged Australians: the Busselton healthy ageing study. Bone. 2015;74:146–52.PubMedCrossRef

46.

Cosman F, Nieves J, Herbert J, et al. High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J Bone Miner Res. 1994;9:1097–105.PubMedCrossRef

47.

Dovio A, Perazzolo L, Osella G, et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab. 2004;89:4923–8.PubMedCrossRef

48.

Aaron JE, Francis RM, Peacock M, et al. Contrasting microanatomy of idiopathic and corticosteroid-induced osteoporosis. Clin Orthop Relat Res. 1989:294–305.

49.

Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357:2028–39.PubMedCrossRef

50.

Cooper C, Steinbuch M, Stevenson R, et al. The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK. Osteoporos Int. 2010;21:569–77.PubMedCrossRef

51.

Ikeuchi K, Hasegawa Y, Seki T, et al. Epidemiology of nontraumatic osteonecrosis of the femoral head in Japan. Mod Rheumatol. 2015;25:278–81.PubMedCrossRef

52.

Kubo T, Ueshima K, Saito M, et al. Clinical and basic research on steroid-induced osteonecrosis of the femoral head in Japan. J Orthop Sci. 2016;21:407–13.PubMedCrossRef

53.

Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002;32(2):94–124. https://doi.org/10.1053/sarh.2002.33724b.PubMedCrossRef

54.

Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin N Am. 2012;41(3):595–611. https://doi.org/10.1016/j.ecl.2012.04.004.CrossRef

55.

Murphey MD, Foreman KL, Klassen-Fischer MK, et al. From the radiologic pathology archives imaging of osteonecrosis: radiologic-pathologic correlation. Radiographics. 2014;34:1003–28.PubMedCrossRef

56.

Dilisio MF. Osteonecrosis following short-term, low-dose oral corticosteroids: a population-based study of 24 million patients. Orthopedics. 2014;37:e631–6.PubMedCrossRef

57.

Chen CH, Chang JK, Lai KA, et al. Alendronate in the prevention of collapse of the femoral head in nontraumatic osteonecrosis: a two-year multicenter, prospective, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012;64:1572–8.PubMedCrossRef

58.

Khaleeli AA, Edwards RH, Gohil K, et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol. 1983;18:155–66.CrossRef

59.

Gupta A, Gupta Y. Glucocorticoid-induced myopathy: pathophysiology, diagnosis, and treatment. Indian J Endocrinol Metab. 2013;17(5):913–6. https://doi.org/10.4103/2230-8210.117215.PubMedPubMedCentralCrossRef

60.

Janssens S, Decramer M. Corticosteroid-induced myopathy and the respiratory muscles. Report of two cases. Chest. 1989;95(5):1160–2. https://doi.org/10.1378/chest.95.5.1160.PubMedCrossRef

61.

Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoid-induced myopathy. J Endocrinol. 2008;197:1–10.PubMedCrossRef

62.

Hasselgren PO, Alamdari N, Aversa Z, et al. Corticosteroids and muscle wasting: role of transcription factors, nuclear cofactors, and hyperacetylation. Curr Opin Clin Nutr Metab Care. 2010;13(4):423–8. https://doi.org/10.1097/MCO.0b013e32833a5107.PubMedPubMedCentralCrossRef

63.

Morgan SA, Hassan-Smith ZK, Doig CL, et al. Glucocorticoids and 11beta-HSD1 are major regulators of intramyocellular protein metabolism. J Endocrinol. 2016;229:277–86.PubMedPubMedCentralCrossRef

64.

Weinstein RS, Chen JR, Powers CC, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest. 2002;109:1041–8.PubMedPubMedCentralCrossRef

65.

Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab. 2000;85:2907–12.PubMed

66.

O'Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004;145:1835–41.PubMedCrossRef

67.

Reid IR. Glucocorticoid osteoporosis--mechanisms and management. Eur J Endocrinol. 1997;137(3):209–17. https://doi.org/10.1530/eje.0.1370209.PubMedCrossRef

68.

Plotkin LI, Weinstein RS, Parfitt AM, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104:1363–74.PubMedPubMedCentralCrossRef

69.

Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet. 2006;367(9522):1605–17. https://doi.org/10.1016/S0140-6736(06)68699-6.PubMedCrossRef

70.

Weinstein RS. Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord. 2001;2(1):65–73. https://doi.org/10.1023/A:1010007108155.PubMedCrossRef

71.

Mazziotti G, Angeli A, Bilezikian JP, et al. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab. 2006;17:144–9.PubMedCrossRef

72.

Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13(10):777–87. https://doi.org/10.1007/s001980200108.PubMedCrossRef

73.

Laan RFJM, Van Riel PLCM, Van de Putte LBA, et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis: a randomized, controlled study. Ann Intern Med. 1993;119:963–8.PubMedCrossRef

74.

Devogelaer JP, Adler RA, Recknor C, et al. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol. 2010;37:141–8.PubMedCrossRef

75.

LoCascio V, Bonucci E, Imbimbo B, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner. 1990;8:39–51.PubMedCrossRef

76.

Jia D, O'Brien CA, Stewart SA, et al. Glucocorticoids act directly on osteoclasts to increase their lifespan and reduce bone density. Endocrinology. 2006;147:5592–9.PubMedPubMedCentralCrossRef

77.

Hofbauer LC, Zeitz U, Schoppet M, et al. Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum. 2009;60:1427–37.PubMedCrossRef

78.

Plotkin LI, Bivi N, Bellido T. A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice. Bone. 2011;49(1):122–7. https://doi.org/10.1016/j.bone.2010.08.011.PubMedCrossRef

79.

Sato AY, Richardson D, Cregor M, et al. Glucocorticoids induce bone and muscle atrophy by tissue-specific mechanisms upstream of E3 ubiquitin ligases. Endocrinology. 2017;158:664–77.PubMed

80.

Leclerc N, Noh T, Cogan J, et al. Opposing effects of glucocorticoids and Wnt signaling on Krox 20 and mineral deposition in osteoblast cultures. J Cell Biochem. 2008;103:1938–51.PubMedCrossRef

81.

Mortensen RF, Shapiro J, Lin BF, et al. Interaction of recombinant IL-1 and recombinant tumor necrosis factor in the induction of mouse acute phase proteins. J Immunol. 1988;140:2260–6.PubMed

82.

Advani S, LaFrancis D, Bogdanovic E, et al. Dexamethasone suppresses in vivo levels of bone collagen synthesis in neonatal mice. Bone. 1997;20:41–6.PubMedCrossRef

83.

Rauch A, Seitz S, Baschant U, et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 2010;11:517–31.PubMedCrossRef

84.

Weinstein RS, Jilka RL, Parfitt AM, et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102:274–82.PubMedPubMedCentralCrossRef

85.

Weinstein RS, Hogan EA, Borrelli MJ, Liachenko S, O’Brien CA, Manolagas SC. The pathophysiological sequence of glucocorticoid-induced osteonecrosis of the femoral head in male mice. Endocrinology. 2017;158(11):3817–31. https://doi.org/10.1210/en.2017-00662.PubMedCrossRef

86.

Fowler TW, Acevedo C, Mazur CM, et al. Glucocorticoid suppression of osteocyte perilacunar remodeling is associated with subchondral bone degeneration in osteonecrosis. Sci Rep. 2017;7:44618.PubMedPubMedCentralCrossRef

87.

Yang M, Trettel LB, Adams DJ, et al. Col 3.6-HSD2 transgenic mice: a glucocorticoid loss-of-function model spanning early and late osteoblast differentiation. Bone. 2010;47:573–82.PubMedPubMedCentralCrossRef

88.

Sher LB, Harrison JR, Adams DJ, et al. Impaired cortical bone acquisition and osteoblast differentiation in mice with osteoblast-targeted disruption of glucocorticoid signaling. Calcif Tissue Int. 2006;79:118–25.PubMedCrossRef

89.

Kalak R, Zhou H, Street J, et al. Endogenous glucocorticoid signalling in osteoblasts is necessary to maintain normal bone structure in mice. Bone. 2009;45:61–7.PubMedCrossRef

90.

Sher LB, Woitge HW, Adams DJ, et al. Transgenic expression of 11beta-hydroxysteroid dehydrogenase type 2 in osteoblasts reveals an anabolic role for endogenous glucocorticoids in bone. Endocrinology. 2004;145:922–9.PubMedCrossRef

91.

Aarden EM, Wassenaar AM, Alblas MJ, et al. Immunocytochemical demonstration of extracellular matrix proteins in isolated osteocytes. Histochem Cell Biol. 1996;106:495–501.PubMedCrossRef

92.

Frendo JL, Xiao G, Fuchs S, et al. Functional hierarchy between two OSE2 elements in the control of osteocalcin gene expression in vivo. J Biol Chem. 1998;273:30509–16.PubMedCrossRef

93.

Cheng SL, Yang JW, Rifas L, et al. Differentiation of human bone marrow osteogenic stromal cells in vitro: induction of the osteoblast phenotype by dexamethasone. Endocrinology. 1994;134:277–86.PubMedCrossRef

94.

Ishida Y, Heersche JN. Glucocorticoid-induced osteoporosis: both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation. J Bone Miner Res. 1998;13(12):1822–6. https://doi.org/10.1359/jbmr.1998.13.12.1822.PubMedCrossRef

95.

Ito S, Suzuki N, Kato S, et al. Glucocorticoids induce the differentiation of a mesenchymal progenitor cell line, ROB-C26 into adipocytes and osteoblasts, but fail to induce terminal osteoblast differentiation. Bone. 2007;40:84–92.PubMedCrossRef

96.

Gohel A, McCarthy MB, Gronowicz G. Estrogen prevents glucocorticoid-induced apoptosis in osteoblasts in vivo and in vitro. Endocrinology. 1999;140(11):5339–47. https://doi.org/10.1210/endo.140.11.7135.PubMedCrossRef

97.

Plotkin LI, Manolagas SC, Bellido T. Glucocorticoids induce osteocyte apoptosis by blocking focal adhesion kinase-mediated survival: evidence for inside-out signaling leading to anoikis. J Biol Chem. 2007;282:24120–30.PubMedCrossRef

98.

Necela BM, Cidlowski JA. Mechanisms of glucocorticoid receptor action in noninflammatory and inflammatory cells. Proc Am Thorac Soc. 2004;1(3):239–46. https://doi.org/10.1513/pats.200402-005MS.PubMedCrossRef

99.

Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711–23. https://doi.org/10.1056/NEJMra050541.PubMedCrossRef

100.

Druilhe A, Letuve S, Pretolani M. Glucocorticoid-induced apoptosis in human eosinophils: mechanisms of action. Apoptosis. 2003;8:481–95.PubMedCrossRef

101.

Limbourg FP, Liao JK. Nontranscriptional actions of the glucocorticoid receptor. J Mol Med. 2003;81(3):168–74. https://doi.org/10.1007/s00109-003-0418-y.PubMedPubMedCentralCrossRef

102.

Chauhan D, Pandey P, Ogata A, et al. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene. 1997;15:837–43.PubMedCrossRef

103.

Blaukat A, Ivankovic-Dikic I, Gronroos E, et al. Adaptor proteins Grb2 and Crk couple Pyk2 with activation of specific mitogen-activated protein kinase cascades. J Biol Chem. 1999;274:14893–901.PubMedCrossRef

104.

Tokiwa G, Dikic I, Lev S, et al. Activation of Pyk2 by stress signals and coupling with JNK signaling pathway. Science. 1996;273:792–4.PubMedCrossRef

105.

Chauhan D, Hideshima T, Pandey P, et al. RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. Oncogene. 1999;18:6733–40.PubMedCrossRef

106.

Xiong W, Parsons JT. Induction of apoptosis after expression of PYK2, a tyrosine kinase structurally related to focal adhesion kinase. J Cell Biol. 1997;139(2):529–39. https://doi.org/10.1083/jcb.139.2.529.PubMedPubMedCentralCrossRef

107.

Sasaki H, Nagura K, Ishino M, et al. Cloning and characterization of cell adhesion kinase beta, a novel protein-tyrosine kinase of the focal adhesion kinase subfamily. J Biol Chem. 1995;270:21206–19.PubMedCrossRef

108.

Avraham H, Park S, Schinkmann K, et al. RAFTK/Pyk2-mediated cellular signalling. Cell Signal. 2000;12:123–33.PubMedCrossRef

109.

Giancotti FG, Ruoslahti E. Integrin signaling. Science. 1999;285(5430):1028–32. https://doi.org/10.1126/science.285.5430.1028.PubMedCrossRef

110.

Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science. 1995;268(5208):233–9. https://doi.org/10.1126/science.7716514.PubMedCrossRef

111.

Frisch SM, Ruoslahti E. Integrins and anoikis. Curr Opin Cell Biol. 1997;9(5):701–6. https://doi.org/10.1016/S0955-0674(97)80124-X.PubMedCrossRef

112.

Ginsberg MH, Partridge A, Shattil SJ. Integrin regulation. Curr Opin Cell Biol. 2005;17(5):509–16. https://doi.org/10.1016/j.ceb.2005.08.010.PubMedCrossRef

113.

Hynes R. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673–87. https://doi.org/10.1016/S0092-8674(02)00971-6.PubMedCrossRef

114.

Plotkin LI, Mathov I, Aguirre JI, et al. Mechanical stimulation prevents osteocyte apoptosis: requirement of integrins, Src kinases and ERKs. Am J Physiol Cell Physiol. 2005;289:C633–43.PubMedCrossRef

115.

Vanden Berghe W, Francesconi E, De Bosscher K, et al. Dissociated glucocorticoids with anti-inflammatory potential repress interleukin-6 gene expression by a nuclear factor-kappaB-dependent mechanism. Mol Pharmacol. 1999;56:797–806.

116.

Cheng SL, Zhang SF, Mohan S, et al. Regulation of insulin-like growth factors I and II and their binding proteins in human bone marrow stromal cells by dexamethasone. J Cell Biochem. 1998;71:449–58.PubMedCrossRef

117.

Chang DJ, Ji C, Kim KK, et al. Reduction in transforming growth factor beta receptor I expression and transcription factor CBFa1 on bone cells by glucocorticoid. J Biol Chem. 1998;273:4892–6.PubMedCrossRef

118.

Doherty WJ, Derome ME, McCarthy MB, et al. The effect of glucocorticoids on osteoblast function. The effect of corticosterone on osteoblast expression of beta 1 integrins. J Bone Joint Surg Am. 1995;77:396–404.PubMedCrossRef

119.

Almeida M, Han L, Ambrogini E, et al. Glucocorticoids and tumor necrosis factor (TNF) alpha increase oxidative stress and suppress WNT signaling in osteoblasts. J Biol Chem. 2011;286:44326–35.PubMedPubMedCentralCrossRef

120.

Harding HP, Zhang Y, Zeng H, et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell. 2003;11:619–33.PubMedCrossRef

121.

Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011;334(6059):1081–6. https://doi.org/10.1126/science.1209038.PubMedCrossRef

122.

Sato AY, Tu X, McAndrews KA, et al. Prevention of glucocorticoid induced-apoptosis of osteoblasts and osteocytes by protecting against endoplasmic reticulum (ER) stress in vitro and in vivo in female mice. Bone. 2015;73:60–8.PubMedCrossRef

123.

Boyce M, Bryant KF, Jousse C, et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science. 2005;307:935–9.PubMedCrossRef

124.

Tsaytler P, Harding HP, Ron D, et al. Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science. 2011;332:91–4.PubMedCrossRef

125.

Yokota H, Hamamura K, Chen A, et al. Effects of salubrinal on development of osteoclasts and osteoblasts from bone marrow-derived cells. BMC Musculoskelet Disord. 2013;14(1):197. https://doi.org/10.1186/1471-2474-14-197.PubMedPubMedCentralCrossRef

126.

Hamamura K, Tanjung N, Yokota H. Suppression of osteoclastogenesis through phosphorylation of eukaryotic translation initiation factor 2 alpha. J Bone Miner Metab. 2013;31(6):618–28. https://doi.org/10.1007/s00774-013-0450-0.PubMedCrossRef

127.

Hamamura K, Yokota H. Stress to endoplasmic reticulum of mouse osteoblasts induces apoptosis and transcriptional activation for bone remodeling. FEBS Lett. 2007;581(9):1769–74. https://doi.org/10.1016/j.febslet.2007.03.063.PubMedPubMedCentralCrossRef

128.

Saito A, Ochiai K, Kondo S, et al. Endoplasmic reticulum stress response mediated by the PERK-eIF2 (alpha)-ATF4 pathway is involved in osteoblast differentiation induced by BMP2. J Biol Chem. 2011;286:4809–18.PubMedCrossRef

129.

Sato AY, Cregor M, Delgado-Calle J, et al. Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of Sost/sclerostin. J Bone Miner Res. 2016;31:1791–802.PubMedCrossRef

130.

Piemontese M, Xiong J, Fujiwara Y, et al. Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice. Am J Physiol Endocrinol Metab. 2016;311(3):E587–93. https://doi.org/10.1152/ajpendo.00219.2016.PubMedPubMedCentralCrossRef

131.

Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009;360:53–62.PubMedPubMedCentralCrossRef

132.

Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19(2):179–92. https://doi.org/10.1038/nm.3074.PubMedCrossRef

133.

Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10:537–43.PubMedCrossRef

134.

Dixon JM, Cull RE, Gamble P. Two cases of van Buchem's disease. J Neurol Neurosurg Psychiatry. 1982;45:913–8.PubMedPubMedCentralCrossRef

135.

Leupin O, Piters E, Halleux C, et al. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem. 2011;286:19489–500.PubMedPubMedCentralCrossRef

136.

Glass DA, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8:751–64.PubMedCrossRef

137.

Holmen SL, Zylstra CR, Mukherjee A, et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem. 2005;280:21162–8.PubMedCrossRef

138.

Jilka RL, Bellido T, Almeida M, Plotkin LI, O'Brien CA, Weinstein RS, et al. Apoptosis in bone cells. In: Bilezikian JP, Raisz LG, Martin TJ, editors. Principles of Bone Biology. San Diego, San Francisco, New York, London, Sydney, Tokyo: Academic Press; 2008. p. 237–61. https://doi.org/10.1016/B978-0-12-373884-4.00032-X.CrossRef

139.

Marenzana M, Greenslade K, Eddleston A, et al. Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum. 2011;63:2385–95.PubMedCrossRef

140.

Yao W, Dai W, Jiang L, et al. Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength. Osteoporos Int. 2016;27:283–94.PubMedCrossRef

141.

van Lierop AH, Hamdy NA. Papapoulos,SE glucocorticoids are not always deleterious for bone. J Bone Miner Res. 2010;25(12):2796–800. https://doi.org/10.1002/jbmr.151.PubMedCrossRef

142.

Rizzoli R, Adachi JD, Cooper C, et al. Management of glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2012;91:225–43.PubMedCrossRef

143.

Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced osteoporosis intervention study group. N Engl J Med. 1998;339:292–9.PubMedCrossRef

144.

Mok CC, Ho LY, Ma KM. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. Bone. 2015;75:222–8.PubMedCrossRef

145.

Allen MR, Iwata K, Phipps R, et al. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone. 2006;39:872–9.PubMedCrossRef

146.

Mashiba T, Turner CH, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 2001;28:524–31.PubMedCrossRef

147.

O'Ryan FS, Khoury S, Liao W, et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg. 2009;67:1363–72.PubMedCrossRef

148.

Allen MR, Burr DB. Mineralization, microdamage, and matrix: how bisphosphonates influence material properties of bone. BoneKEy-osteovision. 2007;4(2):49–60. https://doi.org/10.1138/20060248.CrossRef

149.

Minetto MA, Botter A, Lanfranco F, et al. Muscle fiber conduction slowing and decreased levels of circulating muscle proteins after short-term dexamethasone administration in healthy subjects. J Clin Endocrinol Metab. 2010;95:1663–71.PubMedCrossRef

150.

Minetto MA, Qaisar R, Agoni V, et al. Quantitative and qualitative adaptations of muscle fibers to glucocorticoids. Muscle Nerve. 2015;52:631–9.PubMedCrossRef

151.

Schakman O, Kalista S, Barbe C, et al. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol. 2013;45:2163–72.PubMedCrossRef

152.

Sandri M, Lin J, Handschin C, et al. PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci U S A. 2006;103(44):16260–5. https://doi.org/10.1073/pnas.0607795103.PubMedPubMedCentralCrossRef

153.

Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001;294:1704–8.PubMedCrossRef

154.

Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A. 2001;98(25):14440–5. https://doi.org/10.1073/pnas.251541198.PubMedPubMedCentralCrossRef

155.

Menconi M, Gonnella P, Petkova V, Lecker S, Hasselgren PO. Dexamethasone and corticosterone induce similar, but not identical, muscle wasting responses in cultured L6 and C2C12 myotubes. J Cell Biochem. 2008;105(2):353–64. https://doi.org/10.1002/jcb.21833.PubMedPubMedCentralCrossRef

156.

Furlow JD, Watson ML, Waddell DS, Neff ES, Baehr LM, Ross AP, et al. Altered gene expression patterns in muscle ring finger 1 null mice during denervation- and dexamethasone-induced muscle atrophy. Physiol Genomics. 2013;45(23):1168–85. https://doi.org/10.1152/physiolgenomics.00022.2013.PubMedPubMedCentralCrossRef

157.

Baehr LM, Furlow JD, Bodine SC. Muscle sparing in muscle RING finger 1 null mice: response to synthetic glucocorticoids. J Physiol. 2011;589(19):4759–76. https://doi.org/10.1113/jphysiol.2011.212845.PubMedPubMedCentralCrossRef

158.

Watson ML, Baehr LM, Reichardt HM, et al. A cell-autonomous role for the glucocorticoid receptor in skeletal muscle atrophy induced by systemic glucocorticoid exposure. Am J Physiol Endocrinol Metab. 2012;302(10):E1210–20. https://doi.org/10.1152/ajpendo.00512.2011.PubMedPubMedCentralCrossRef

159.

Sartori R, Schirwis E, Blaauw B, Bortolanza S, Zhao J, Enzo E, et al. BMP signaling controls muscle mass. Nat Genet. 2013;45(11):1309–18. https://doi.org/10.1038/ng.2772.PubMedCrossRef

160.

Kondo H, Ezura Y, Nakamoto T, Hayata T, Notomi T, Sorimachi H, et al. MURF1 deficiency suppresses unloading-induced effects on osteoblasts and osteoclasts to lead to bone loss. J Cell Biochem. 2011;112(12):3525–30. https://doi.org/10.1002/jcb.23327.PubMedCrossRef

161.

Fournier M, Huang ZS, Li H, Da X, Cercek B, Lewis MI. Insulin-like growth factor I prevents corticosteroid-induced diaphragm muscle atrophy in emphysematous hamsters. Am J Physiol Regul Integr Comp Physiol. 2003;285(1):R34–43. https://doi.org/10.1152/ajpregu.00177.2002.PubMedCrossRef

162.

Dekhuijzen PN, Gayan-Ramirez G, Bisschop A, de Bock V, Dom R, Decramer M. Corticosteroid treatment and nutritional deprivation cause a different pattern of atrophy in rat diaphragm. J Appl Physiol. 1995;78(2):629–37. https://doi.org/10.1152/jappl.1995.78.2.629.PubMedCrossRef

163.

Rosenblatt JD, Parry DJ. Gamma irradiation prevents compensatory hypertrophy of overloaded mouse extensor digitorum longus muscle. J Appl Physiol (1985). 1992;73:2538–43.CrossRef

164.

Falduto MT, Czerwinski SM, Hickson RC. Glucocorticoid-induced muscle atrophy prevention by exercise in fast-twitch fibers. J Appl Physiol. 1990;69(3):1058–62. https://doi.org/10.1152/jappl.1990.69.3.1058.PubMedCrossRef

165.

Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004;117(3):399–412. https://doi.org/10.1016/S0092-8674(04)00400-3.PubMedPubMedCentralCrossRef

166.

Milan G, Romanello V, Pescatore F, Armani A, Paik JH, Frasson L, et al. Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy. Nat Commun. 2015;6(1):6670. https://doi.org/10.1038/ncomms7670.PubMedPubMedCentralCrossRef

167.

Mourikis P, Sambasivan R, Castel D, Rocheteau P, Bizzarro V, Tajbakhsh S. A critical requirement for notch signaling in maintenance of the quiescent skeletal muscle stem cell state. Stem Cells. 2012;30(2):243–52. https://doi.org/10.1002/stem.775.PubMedCrossRef

168.

Wen Y, Bi P, Liu W, Asakura A, Keller C, Kuang S. Constitutive notch activation upregulates Pax7 and promotes the self-renewal of skeletal muscle satellite cells. Mol Cell Biol. 2012;32(12):2300–11. https://doi.org/10.1128/MCB.06753-11.PubMedPubMedCentralCrossRef

169.

Buas MF, Kabak S, Kadesch T. The notch effector Hey1 associates with myogenic target genes to repress myogenesis. J Biol Chem. 2010;285(2):1249–58. https://doi.org/10.1074/jbc.M109.046441.PubMedCrossRef

170.

Kopan R, Nye JS, Weintraub H. The intracellular domain of mouse notch: a constitutively activated repressor of myogenesis directed at the basic helix-loop-helix region of MyoD. Development. 1994;120(9):2385–96.PubMed

171.

Pereira RM, Delany AM, Durant D, et al. Cortisol regulates the expression of notch in osteoblasts. J Cell Biochem. 2002;85(2):252–8. https://doi.org/10.1002/jcb.10125.PubMedCrossRef

172.

Xu J, Li R, Workeneh B, Dong Y, Wang X, Hu Z. Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486. Kidney Int. 2012;82(4):401–11. https://doi.org/10.1038/ki.2012.84.PubMedPubMedCentralCrossRef

173.

Ambrogini E, Almeida M, Martin-Millan M, Paik JH, DePinho RA, Han L, et al. FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab. 2010;11(2):136–46. https://doi.org/10.1016/j.cmet.2009.12.009.PubMedPubMedCentralCrossRef

Titel: Glucocorticoid Excess in Bone and Muscle
verfasst von: Amy Y. Sato
Munro Peacock
Teresita Bellido
Publikationsdatum: 05.02.2018
Verlag: Springer US
Erschienen in: Clinical & Translational Metabolism / Ausgabe 1/2018
Print ISSN: 1534-8644
Elektronische ISSN: 2948-2445
DOI: https://doi.org/10.1007/s12018-018-9242-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Glucocorticoid Excess in Bone and Muscle

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Acknowledgement for Reviewers 2017

Effects of Bazedoxifene on Bone Mineral Density and Fracture in Post-Menopausal Osteoporotic Women: a Systematic Review and Meta-Analysis

2018—Changing Times for CRBM

Myokine—Irisin—and Its Effects Linking Bone and Muscle Function

Stress and Insufficiency Fractures

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin